Investigational drug · Phase 2
LW231
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic HBV Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "LW231"
First trial start
2025
Nov 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LW231", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic HBV Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "LW231" as an intervention, largest first.
- Study of LW231 in Participants With Chronic Hepatitis BPivotal-lookingRecruiting
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT07179575 · 270 participants (planned) · Start Nov 11, 2025 · Primary completion Mar 2027
Drug: LW231; LW231 placebo · For: Chronic HBV Infection
Sites: Hangzhou, China · 2 sites in all
- A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus InfectionPivotal-lookingCompleted
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT06311734 · 119 participants · Start Jun 21, 2022 · Primary completion Jan 1, 2024
Drug: LW231 tablets; Placebo · For: Chronic Hepatitis B
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.